Drugs / CD19-7×19 CAR-T
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05659628 | Dec 2022 → Dec 2024 overdue | diffuse large B-cell lymphoma | Ningbo No. 1 Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04381741 | Jun 2020 → Sep 2023 | diffuse large B-cell lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-7×19 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04381741 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T cell (CAR-T) therapy” NCT04381741 ↗ |
| Target | CD19 | “CD19 CAR-T treatment” NCT04381741 ↗ |